MIR3152: A Potential Drug Target and Biomarker (G100422869)
MIR3152: A Potential Drug Target and Biomarker
MIR3152 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for drug developers. In this article, we will explore the potential of MIR3152 as a drug target and biomarker.
The MIR3152 molecule
MIR3152 is a non-coding RNA molecule that contains 21 amino acid residues. It has a unique structure, with a 21 amino acid long terminal extension that is rich in positively charged amino acids. This structure gives MIR3152 a unique property that makes it a potential drug target.
MIR3152 functions as a negative regulator of the microRNA (miRNA) pathway. The miRNA pathway is a complex process that regulates gene expression by controlling the translation of mRNAs into proteins. MIR3152 plays a crucial role in the regulation of miRNA expression by binding to the miRNA binding site on target mRNAs and preventing their translation into proteins.
MIR3152's unique structure and function have made it an attractive target for drug developers. The combination of its small size and unique structure has made it easy to manipulate and study. This has led to a great deal of interest in the potential of MIR3152 as a drug target and biomarker.
MIR3152 as a drug target
MIR3152 has been identified as a potential drug target for various diseases, including cancer. Its unique structure and function make it an attractive target for drug developers.
One of the potential reasons for MIR3152's potential as a drug target is its unique structure. The 21 amino acid long terminal extension of MIR3152 is rich in positively charged amino acids, which makes it a likely target for small molecules that can interact with these amino acids. This has led to the development of several compounds that have been shown to interact with MIR3152 and inhibit its activity as a negative regulator of the miRNA pathway.
Another potential reason for MIR3152's potential as a drug target is its location on the body's cell surface. MIR3152 is expressed in most tissues and cells of the body, including those of cancer cells. This makes it an attractive target for drugs that can inhibit its activity and reduce the number of cancer cells in the body.
MIR3152 has also been shown to be involved in several diseases, including cancer. For example, studies have shown that MIR3152 is overexpressed in various types of cancer, including breast, lung, and ovarian cancer. This overexpression has been shown to contribute to the development and progression of these diseases.
MIR3152 as a biomarker
MIR3152 has also been identified as a potential biomarker for several diseases, including cancer. Its unique structure and function make it an attractive target for diagnostic tests.
One of the potential reasons for MIR3152's potential as a biomarker is its location on the body's cell surface. As a cell surface protein, MIR3152 is easily accessible to diagnostic tests, making it an attractive target for biomarkers.
Another potential reason for MIR3152's potential as a biomarker is its involvement in several diseases, including cancer. Studies have shown that MIR3152 is overexpressed in various types of cancer, including breast, lung, and ovarian cancer. This overexpression has
Protein Name: MicroRNA 3152
The "MIR3152 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3152 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2 | MIR3156-3 | MIR3157 | MIR3158-1 | MIR3158-2 | MIR3159 | MIR3160-1 | MIR3160-2 | MIR3161 | MIR3162 | MIR3163 | MIR3164 | MIR3165 | MIR3166 | MIR3167 | MIR3168 | MIR3169 | MIR3170 | MIR3171 | MIR3171HG | MIR3173 | MIR3174 | MIR3175 | MIR3176 | MIR3177 | MIR3178 | MIR3179-1 | MIR3179-2 | MIR3179-3 | MIR3180-1 | MIR3180-2 | MIR3180-3 | MIR3180-4 | MIR3180-5 | MIR3182 | MIR3183 | MIR3184 | MIR3185 | MIR3186 | MIR3187 | MIR3188 | MIR3189 | MIR3190 | MIR3191 | MIR3192 | MIR3193 | MIR3194 | MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605
